Showing results (2201-2210 of 2,282) with videos related to

Sort By:
Pageof 229
Cell|June 17, 2008
Integration of external signaling pathways with the core transcriptional network in embryonic stem cellsXi Chen, Han Xu, Ping Yuan, et al.
Voprosy Onkologii|January 1, 1996
[Preliminary results of the Russia (St.Petersburg)/WHO program for the evaluation of the effectiveness of breast self-examination]V F Semiglazov, V M Moiseenko, S A Protsenko, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2023
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset AnalysisRoss A Soo, Byoung Chul Cho, Joo-Hang Kim, et al.
Oncology Research and Treatment|August 27, 2018
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on ArtifactsElena D Lavdovskaia, Aglaya G Iyevleva, Anna P Sokolenko, et al.
Molecular Phylogenetics and Evolution|March 14, 2018
Large-scale phylogenetic analyses provide insights into unrecognized diversity and historical biogeography of Asian leaf-litter frogs, genus Leptolalax (Anura: Megophryidae)Jin-Min Chen, Nikolay A Poyarkov, Chatmongkon Suwannapoom, et al.
The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.
Chemical Biology & Drug Design|May 24, 2024
Phenotypic assessment of antiviral activity for spiro-annulated oxepanes and azepenesDmitry I Osolodkin, Liubov I Kozlovskaya, Ildar R Iusupov, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 24, 2022
Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illnessEric D Morrell, Pavan K Bhatraju, Neha A Sathe, et al.
Oncotarget|September 9, 2017
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumorsDmitry M Ponomarenko, Irina D Klimova, Yulia A Chapygina, et al.
Pageof 229